Filing Flows › Seres Therapeutics (MCRB) › Q3 2026 › vs Q3 2025
Seres Therapeutics (MCRB) Q3 2026 vs Q3 2025 (year over year)
Seres Therapeutics's revenue rose $242K (+69%) from $351K in Q3 2025 to $593K in Q3 2026.
Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year), net loss $16.3M, operating cash flow −$10.5M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $593K | $351K | $242K | +69% |
| Net loss | $16.3M | −$8.2M | $24.5M | — |
| Costs & expenses | $16.9M | $31.0M | −$14.2M | -46% |
| Operating costs | $16.7M | $22.8M | −$6.1M | -27% |
| Interest & other, net | $134K | −$30.7M | $30.8M | — |
| Research & development | $5.6M | $12.6M | −$7.0M | -56% |
| General & admin | $5.4M | $9.5M | −$4.0M | -43% |
| Other operating costs | $5.7M | $736K | $5.0M | +675% |
| Operating cash sources | $16.3M | −$8.2M | $24.5M | — |
| Depreciation & amortization | $481K | $1.0M | −$563K | -54% |
| Share-based compensation | $1.9M | $2.5M | −$623K | -25% |
| Working capital & other | $3.5M | −$9.5M | $13.0M | — |
| Cash used in operations | $10.5M | −$2.2M | $12.7M | — |
| Net loss absorbed | $16.3M | −$8.2M | $24.5M | — |
Questions
How much did Seres Therapeutics's revenue grow year over year in Q3 2026?
Seres Therapeutics's revenue rose $242K (+69%) from $351K in Q3 2025 to $593K in Q3 2026.